Hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors does not appear to prevent the incidence of breast cancer when taken jointly; however, statins, and more specifically, lipophilic statins, might be a viable approach to protect breast cancer diagnosed patients against breast cancer relapse and mortality [53]. This evidence concerns the gene HMGCR and breast carcinoma.